Although rituximab does not carry an indication for the treatment of neurological disorders, the drug is widely used off-label as a therapy for B-cell–mediated disorders like multiple sclerosis (MS). Given the fact that rituximab has not been approved in these indications, however, data that reflect its safety and efficacy—particularly in patient populations for whom data are particularly scarce—are crucial.
Although rituximab does not carry an indication for the treatment of neurological disorders, the drug is widely used off-label as a therapy for B-cell—mediated disorders like multiple sclerosis (MS). The approval of the first US-licensed biosimilar rituximab, Truxima, in 2018, has the potential to make this high-cost treatment option available to more patients, both in its approved indications in oncology and in such off-label applications as the treatment of MS.
Given the fact that rituximab has not been approved in these indications, however, data that reflect its safety and efficacy—particularly in patient populations for whom data are particularly scarce—are crucial. During the upcoming Academy of American Neurology meeting, which will be held May 4-10 in Philadelphia, Pennsylvania, multiple researchers will present on the use of rituximab in patients with MS who are pregnant or breastfeeding.
First, Jessica Rice, MD, of the Oregon Health and Science University in Portland, Oregon, will present a case series in which patients with MS had increased disease activity during pregnancy, although the usual rate of MS relapse typically declines during pregnancy, and many pregnant patients stop taking disease-modifying therapy given concerns about safety.1
In these 2 cases, patients experienced disabling symptoms, and there was concern about further relapses during pregnancy, so the patients were treated with rituximab after risk/benefit considerations.
The first patient, who was treated with rituximab during the third trimester, showed improvement over several weeks, and her infant was born at term without complications. The second patient was treated with rituximab in the early second trimester and has also shown improvement. This patient was in the third trimester at the time of the abstract submission, but no complications had been identified up to that date.
Rice concluded that treating aggressive MS with rituximab during pregnancy has risks, but the drug may be safe and effective when used in an appropriate context.
Researchers from the University of California, San Francisco’s Department of Neurology will report on the concentration of rituximab in the breastmilk of breastfeeding patients with MS. Currently, write the researchers, women with MS have a high risk of postpartum relapse, but due to a lack of data, the standard of care is for them to choose between breastfeeding and resuming MS treatment.2
In the single-center study, the researches collected 6 samples of breast milk from 4 lactating patients who were receiving rituximab. The samples were analyzed using an enzyme-linked immunosorbent assay. The researchers detected only minimal concentrations of rituximab in the samples.
Although the sample size was small, this largest-to-date study of rituximab concentration in breast milk establishes the need for a larger longitudinal study that includes infant outcome measures.
References
1. Rice J. Rituximab for treatment of aggressive multiple sclerosis during pregnancy: a case study. Presented at: 2019 Academy of American Neurology Annual Meeting, May 4-10, 2019; Philadelphia, PA. Abstract P4.2-103.
2. LaHue S, Krysko K, Rutatangwa A, et al. Minimal concentrations of rituximab in the breastmilk of women treated for multiple sclerosis. Presented at: 2019 Academy of American Neurology Annual Meeting, May 4-10, 2019; Philadelphia, PA. Abstract P4.2-097.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.